title: Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritus after cesarean delivery.
abstract: In this prospective, randomized, double-blinded study, we compared the efficacy of nalbuphine and propofol for treating intrathecal morphine-induced pruritus after cesarean delivery. One-hundred-eighty-one parturients who developed moderate to severe pruritus after the administration of intrathecal morphine were randomly allocated into two groups. One group received 3 mg IV nalbuphine (n = 91), and the other received 20 mg IV propofol (n = 90). The improvement of pruritus and other adverse effects was determined at 10 min after study drug administration. The treatment success rate was higher in the Nalbuphine group than in the Propofol group (83% vs 61%; P < 0.001). Among the successfully treated patients, recurrence rates of moderate to severe pruritus within 4 h were not significantly different (nalbuphine 9% versus propofol 7%; P = 0.76). Other side effects, such as decreased analgesia, increased nausea, vomiting, increased sedation, pain on injection, and dizziness, were not significantly different between groups. Sedation and pain on injection, which were the two most common side effects, were minor and clinically inconsequential.
  
  
  CONCLUSIONS
  Nalbuphine was superior to propofol for the treatment of intrathecal morphine-induced pruritus after cesarean delivery.
authors: Department of Anesthesiology, the Clinical Epidemiology Unit, Bangkok, Thailand.
authors: S
authors: S
authors: Charuluxananan
authors: O
authors: O
authors: Kyokong
authors: W
authors: W
authors: Somboonviboon
authors: S
authors: S
authors: Lertmaharit
authors: P
authors: P
authors: Ngamprasertwong
authors: K
authors: K
authors: Nimcharoendee
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D002585:Cesarean Section; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D009020:Morphine / Q000009:adverse effects*; D009266:Nalbuphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000139:chemically induced / Q000188:drug therapy*; D011247:Pregnancy; D011446:Prospective Studies; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000701:Analgesics, Opioid; D009020:Morphine; D009266:Nalbuphine